Inoviq
Inoviq is an Australian biotechnology company focused on developing and commercializing innovative cancer diagnostic products. The company's focus is on improving cancer detection and monitoring through its proprietary technologies. Inoviq aims to address unmet needs in cancer diagnostics, offering potential benefits for patients and healthcare providers.
Short position
Inoviq (ASX:IIQ) has 0.00% of its shares on issue reported as short positions as of 5 Oct 2026, or about 27 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has been broadly flat. Its highest recorded short interest was 0.58% in October 2025. IIQ is classified in the Health Care Equipment & Services industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4Inoviq (IIQ) financials
Results, ratios and statements
Latest result
Year to 30 Jun 2026 (FY26) vs FY25, figures in AUD, the reporting currency
- Revenue
- $432.0Kvs n/a (FY25)
- Yahoo Finance, as at 29 Sep 2026
- NPAT
- −$7.5Mvs n/a (FY25)
- Yahoo Finance, as at 29 Sep 2026
- EPS (diluted)
- −$0.057vs −$0.062 (FY25)
- Yahoo Finance, as at 29 Sep 2026
- Rev YoY
- n/aFY
- EPS YoY
- n/aTTM
Summary of 2026 Annual Report, 17 Sep 2026
INOVIQ reported a net loss of $7.51 million for FY26, reflecting continued investment in its diagnostic and therapeutic programs. No dividend was declared. The company is focused on advancing its EXO-OC ovarian cancer test toward commercialisation as a Laboratory Developed Test in the US and progressing its CAR-exosome therapeutics toward first-in-human studies, with a cash position of $9.4 million to fund operations.
Automated summary of the filing; the filing itself is the record.
Key ratios
Year to 30 Jun 2026 (FY); balance sheet at 30 Jun 2026; prices to 9 Oct 2026
- Gross margin
- 82.2%
- Operating margin
- −2,223.2%
- Net margin
- −1,737.1%
- FCF margin
- −1,515.7%
- ROE
- n/a
- ROA
- n/a
- FCF conversion
- n/a
- Net debt (excl. leases)
- n/a
- Net debt / EBITDA
- n/a
- Current ratio
- 9.4×
- Interest cover
- n/a
- Cash dividends paid / net profit
- n/a
- Market cap
- $21.8M
- P/E
- n/a
- P/B
- 1.2×
Ratios use the reporting currency (AUD); market cap is in AUD. Source: Yahoo Finance, as at 29 Sep 2026.
Financial statements
Figures in AUD, the reporting currency; Yahoo Finance unless marked
| Line item | FY26 | FY25 | FY24 | FY23 |
|---|---|---|---|---|
| Revenue | $432.0K | n/a | $535.1K | $398.2K |
| Gross profit | $355.3K | n/a | $454.1K | $353.7K |
| Operating income | −$9.6M | n/a | −$7.8M | −$10.5M |
| EBITDA | −$8.3M | n/a | −$6.6M | −$9.3M |
| EBIT | −$9.6M | n/a | −$7.8M | −$10.5M |
| Pretax income | −$7.5M | n/a | −$6.6M | −$9.0M |
| Tax | $0 | n/a | $0 | $0 |
| NPAT | −$7.5M | n/a | −$6.6M | −$9.0M |
| Net interest income | $379.0K | n/a | $256.6K | $353.7K |
| EPS basic | −$0.057 | −$0.062 | −$0.071 | −$0.098 |
| EPS diluted | −$0.057 | −$0.062 | −$0.071 | −$0.098 |
| Shares | 140.8M | n/a | 105.5M | 92.0M |
Financial reports
The company's own filings, newest first
- 2026 Annual ReportAnnual Report17 Sep 2026via asx_announcements
- Appendix 4E and Preliminary Financial ReportAnnual Results27 Aug 2026via asx_announcements
- Quarterly Activities Report and Appendix 4C - June 2026Quarterly Report13 Jul 2026via asx_announcements
- Quarterly Activities Report and Appendix 4C - March 2026Quarterly Report28 Apr 2026via asx_announcements
- Appendix 4D and FY26 Half Year Financial ReportHalf Year Results18 Feb 2026via asx_announcements
- Quarterly Business Update and Appendix 4C - December 2025Quarterly Report29 Jan 2026via asx_announcements
- Quarterly Business Update and Appendix 4C - September 2025Quarterly Report29 Oct 2025via asx_announcements
- 2025 Annual ReportAnnual Report18 Sep 2025via asx_announcements
- Appendix 4E and Preliminary Financial ReportAnnual Results22 Aug 2025via asx_announcements
- Quarterly Business Update and Appendix 4C - June 2025Quarterly Report31 Jul 2025via asx_announcements
Showing 10 of 22 reports